Other substances

Radotinib

A tyrosine kinase inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
3
 AI-suggested references
0
 Clinical trials

General information

Radotinib is a tyrosine kinase inhibitor acting on Bcr-Abl fusion protein and platelet-derived growth factor receptor. It manifests antineoplastic activity in Philadelphia chromosome-positive chronic myeloid leukaemia cells (NCI).

Radotinib on DrugBank
Radotinib on PubChem
Radotinib on Wikipedia

 

Structure image - Radotinib

CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=NC=CN=C5

Supporting references

Link Tested on Impact factor Notes Publication date
Systemic in Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server
in silico 4.55

Predicted to bind a SARS-CoV-2 protein structural feature.

 Aug/11/2020

AI-suggested references

Link Publication date
Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing.
Mar/11/2022
Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches
Apr/07/2022
Proposition of a new allosteric binding site for potential SARS-CoV-2 3CL protease inhibitors by utilizing molecular dynamics simulations and ensemble docking
Oct/28/2021
Export (.csv)